Join to View Full Profile
1515 Holcombe BlvdHouston, TX 77030
Phone+1 713-792-6161
Dr. Green is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Texas Health Science Center at HoustonFellowship, Hematology and Medical Oncology, 1998 - 2001
University of Virginia Medical CenterResidency, Internal Medicine, 1995 - 1998
University of Texas Medical Branch School of MedicineClass of 1995
Certifications & Licensure
TX State Medical License 2000 - 2026
MA State Medical License 1981 - 2017
Clinical Trials
- CT-2103 in Combination With Gemcitabine in Metastatic Breast Cancer Start of enrollment: 2005 Dec 01
Publications & Presentations
PubMed
- 415 citationsMolecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis BlockadeRobert J. Motzer, Romain Banchereau, Habib Hamidi, Thomas Powles, David F. McDermott
Cancer Cell. 2020-12-14 - 768 citationsAtezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3,...Brian I. Rini, Thomas Powles, Michael B. Atkins, Bernard Escudier, David F. McDermott
Lancet. 2019-06-15 - 4078 citationsTGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells.Sanjeev Mariathasan, Shannon J. Turley, Dorothee Nickles, Alessandra Castiglioni, Kobe C. Yuen
Nature. 2018-02-22
Press Mentions
“Game-Changing” Keytruda-Padcev Combo Gets FDA Nod for Muscle-Invasive Bladder CancerDecember 4th, 2025- Merck Keytruda Wins European Commission Nod for Locally Advanced Head, Neck Squamous Cell CarcinomaOctober 29th, 2025
- Merck Gets USFDA Priority Review for 2 Applications for Keytruda, Keytruda Qlex in Combo with Padcev for Bladder CancerOctober 24th, 2025
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
